Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wr-Crcn LLC

Neither a doctor nor a teaching hospital

Research payments

$4,337,303

544 payments

Through program year 2025, Wr-Crcn LLC is reported as receiving $4,337,303 in research payments, across 544 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $284,013 109
2024 Research $306,928 112
2023 Research $1,412,863 66
2022 Research $864,185 31
2021 Research $914,637 27
2020 Research $554,677 199

Breakdown

Who paid Research payments · program years 2020–2025
  1. Janssen Research & Development, LLC $2,311,301 78 payments
  2. Bavarian Nordic A/S $932,396 7 payments
  3. Novavax Inc $313,058 32 payments
  4. Eli Lilly and Company $258,030 8 payments
  5. AbbVie, Inc. $218,428 20 payments
  6. Emergent BioSolutions Inc. $100,107 184 payments
  7. Teva Pharmaceuticals USA, Inc. $93,065 182 payments
  8. Allergan Inc. $35,786 7 payments
  9. Genentech, Inc. $21,458 4 payments
  10. AstraZeneca Pharmaceuticals LP $19,737 2 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants $1,782,328 53 payments
  2. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $562,655 5 payments
  3. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants $439,648 6 payments
  4. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $369,741 2 payments
  5. A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 $296,469 30 payments
  6. A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (Achieve-3) $246,070 4 payments
  7. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $166,417 13 payments
  8. Tv50717-Cns-40223 $93,065 182 payments
  9. A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults $89,325 19 payments
  10. VELOCITY: An Anthrax Vaccine Clinical Study $53,680 183 payments
What the money was spent on Research payments · program years 2020–2025
  1. Patient care $7,700 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record